| Recruiting | Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) fo NCT06498648 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who NCT06981637 | National Health Research Institutes, Taiwan | Phase 2 |
| Recruiting | Actinium Therapy for Late-stage Aggressive Sarcomas NCT07156565 | Ratio Therapeutics, Inc. | Phase 1 |
| Recruiting | A Trial of Cadonilimab With Adriamycin in Patients With Advanced Soft Tissue Sarcoma NCT06367075 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 |
| Withdrawn | Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanc NCT06370871 | Boehringer Ingelheim | Phase 3 |
| Recruiting | LINNOVATE: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue Sarcoma NCT05876715 | ERLINDA M GORDON | Phase 1 / Phase 2 |
| Active Not Recruiting | Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas NCT05809830 | Grupo Espanol de Investigacion en Sarcomas | Phase 1 / Phase 2 |
| Recruiting | Geno-radiomics Based Model for Evaluation of Immunotherapy and Targeted Therapy for Advanced Soft Tissue Sarco NCT06062927 | Peking Union Medical College Hospital | — |
| Recruiting | Study of NY-ESO-1 TCR-T in Advanced Soft Tissue Sarcoma NCT05620693 | Shenzhen University General Hospital | N/A |
| Recruiting | Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial NCT05333458 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas NCT05182164 | Institut Bergonié | Phase 2 |
| Active Not Recruiting | HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas NCT05180695 | Centre Leon Berard | Phase 1 / Phase 2 |
| Terminated | A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft Tissue Sarcoma NCT04780464 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 |
| Recruiting | Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma NCT04874311 | Institut Bergonié | Phase 2 |
| Active Not Recruiting | Lurbinectedin + Doxorubicin In Leiomyosarcoma NCT05099666 | Massachusetts General Hospital | Phase 1 / Phase 2 |
| Terminated | Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant Tumors NCT05154630 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Multicohort Trial of Different Schemes of PM14 in Monotherapy and in Combination with Radiotherapy in Soft Tis NCT05146440 | Grupo Espanol de Investigacion en Sarcomas | Phase 1 / Phase 2 |
| Terminated | Camsirubicin + Pegfilgrastim to Determine MTD in ASTS NCT05043649 | Monopar Therapeutics | Phase 1 |
| Completed | Combining Epigenetic And Immune Therapy to Beat Cancer. NCT04705818 | Institut Bergonié | Phase 2 |
| Recruiting | Comparison of Oral Cyclophosphamide vs Doxorubicin in ≥65 Years Old Advanced or Metastatic Soft Tissue Sarcoma NCT04757337 | UNICANCER | Phase 3 |
| Completed | Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatme NCT03838744 | Italian Sarcoma Group | Phase 2 |
| Recruiting | Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas NCT04028063 | University of Colorado, Denver | Phase 2 |
| Terminated | Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma NCT04204941 | Epizyme, Inc. | Phase 1 |
| Terminated | Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas NCT03670069 | Fred Hutchinson Cancer Center | Phase 1 |
| Terminated | Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcoma NCT03660930 | University of Washington | Phase 1 / Phase 2 |
| Terminated | OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients NCT03698227 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Phase 2 |
| Recruiting | SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma NCT03138161 | Sarcoma Oncology Research Center, LLC | Phase 1 / Phase 2 |
| Completed | Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot B NCT03009201 | OHSU Knight Cancer Institute | Phase 1 |
| Completed | Geriatric Assessmen of Elderly "Unsuited" Patients Receiving Trabectedin in First Line Treatment For Advanced NCT03022448 | GWT-TUD GmbH | — |
| Completed | A Multicenter, Prospective, oBservational Study to assEss the Clinical activitY and Impact on symptOm Burden a NCT02618122 | Genesis Pharma S.A. | — |
| Completed | A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patient NCT01975519 | Tracon Pharmaceuticals Inc. | Phase 1 / Phase 2 |
| Completed | Gemcitabine Plus Rapamycin Versus Gemcitabine to Treat Advanced Soft Tissue Sarcoma NCT01684449 | Grupo Espanol de Investigacion en Sarcomas | Phase 1 / Phase 2 |